Indaptus Therapeutics Inc. (INDP) saw an uptrend of 3.02% in the recent trading with $7.84 being its most recent. The current price level -78.70% lower than the highest price of $36.80 marked by the stock while trading over the past 52-weeks, whereas it is 14.87% higher than the lowest price of $6.82 the company dropped to over past 52-weeks. The latest news story on INDP appeared in GlobeNewswire under the title “Indaptus Therapeutics Receives Notice of Allowance for Strategic Patent” on Sep-15-21.
Squeezing the time span to 30 day period shows us the stock is currently trading -72.81% below one month high and is +14.87% above of the lowest during that time.
Indaptus Therapeutics Inc. Earnings – What Happened With INDP
Coming around sales and income figures, publically trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
INDP – Indaptus Therapeutics Inc. Stock Earnings Estimates
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 5.03 million. INDP does have institutional investors; and they hold 4.40% of the stock.
Indaptus Therapeutics Inc. – Insider Activity and Holdings
Moreover, the latest SEC filings also revealed that stock came across 1 new insider purchases involving 12,000 shares. On the other hand, INDP declared 0 shares have been sold in 0 insider transactions over the past three months.
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, current ratio recorded by Indaptus Therapeutics Inc. was 2.81 while posting a debt to equity ratio of 0.00. The count was 2.33 for long-term debt to equity ratio.
Indaptus Therapeutics Inc.’s return on equity, or ROE, is -131.10%, compared to the industry average of -68.79% for Healthcare – Biotechnology. Although this indicates that INDP fails to use its equity well, the metric will vary significantly depending on the industry.